TNGX
Tango Therapeutics Inc
NASDAQ: TNGX · HEALTHCARE · BIOTECHNOLOGY
$20.98
-2.96% today
Updated 2026-05-01
Market cap
$3.18B
P/E ratio
—
P/S ratio
51.01x
EPS (TTM)
$-0.87
Dividend yield
—
52W range
$1 – $28
Volume
3.5M
Tango Therapeutics Inc (TNGX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-162.90%
Operating margin
-178.40%
ROE
-37.20%
ROA
-19.50%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2019 | $24.65M | $-14.10M | -30.93% | -61.51% | -57.18% |
| 2020 | $7.66M | $-51.97M | 78.77% | -681.82% | -678.84% |
| 2021 | $37.04M | $-58.23M | 100.00% | -157.09% | -157.21% |
| 2022 | $24.86M | $-108.18M | 100.00% | -446.79% | -435.14% |
| 2023 | $36.53M | $-101.74M | 100.00% | -312.57% | -278.54% |
| 2024 | $42.07M | $-130.30M | 100.00% | -346.09% | -309.73% |
| 2025 | $62.38M | $-101.59M | 96.34% | -178.39% | -162.85% |